| Persistent oligoarticular JIA (n = 78) | Extended oligoarticular JIA (n = 56) | Polyarticular JIA RF- (n = 103) | Polyarticular JIA RF + (n = 26) | ERA (n = 62) | Total (n = 325) |
---|---|---|---|---|---|---|
c-DMARD | ||||||
 Number of distinct c-DMARD prescribed (n, %) | ||||||
  0 | 40 (51%) | 6 (11%) | 0 (0%) | 0 (0%) | 7 (11%) | 53 (16%) |
  1 | 32 (41%) | 37 (66%) | 65 (63%) | 16 (62%) | 38 (62%) | 188 (58%) |
   ≥ 2 | 6 (8%) | 13 (23%) | 37 (37%) | 10 (38%) | 17 (27%) | 84 (26%) |
 c-DMARD types (n, %) | ||||||
  Methotrexate | 34 (44%) | 45 (80%) | 99 (96%) | 26 (100%) | 39 (63%) | 243 (75%) |
  Sulfasalazine |  < 5 (< 6%) | 7 (12%) | 21 (20%) |  < 5 (< 19%) | 30 (48%) | 66 (20%) |
  HCQ | 5 (6%) | 6 (11%) | 16 (16%) | 6 (23%) |  < 5 (< 8%) | 36 (11%) |
  Leflunomide |  < 5 (< 6%) | 6 (11%) | 13 (13%) |  < 5 (< 19%) |  < 5 (< 8%) | 26 (8%) |
 c-DMARD therapy combination | ||||||
  Double c-DMARD | 5 (6.4%) | 8 (14%) | 27 (26%) | 9 (35%) | 12 (19%) | 61 (19%) |
  Triple c-DMARD | 0 |  < 5 (< 9%) |  < 5 (< 5%) |  < 5 (< 19%) | 0 | 5 (2%) |
b-DMARD | ||||||
 Number of distinct b-DMARD prescribed (n, %) | ||||||
  0 | 69 (88%) | 31 (55%) | 40 (39%) | 8 (31%) | 30 (48%) | 178 (55%) |
  1 | 9 (12%) | 22 (39%) | 46 (45%) | 13 (50%) | 21 (34%) | 111 (34%) |
   ≥ 2 | 0 |  < 5 (< 9%) | 17 (16%) | 5 (19%) | 11 (18%) | 36 (11%) |
 b-DMARD types (n, %) | ||||||
  Etanercept |  < 5 (< 6%) | 14 (25%) | 44 (43%) | 15 (58%) | 25 (40%) | 102 (31%) |
  Adalimumab |  < 5 (< 6%) | 9 (16%) | 21 (20%) |  < 5 (< 19%) | 13 (21%) | 51 (16%) |
  Tocilizumab |  < 5 (< 6%) |  < 5 (< 9%) | 11 (11%) |  < 5 (< 19%) |  < 5 (< 8%) | 17 (5%) |
  Othersa | 0 |  < 5 (< 9%) | 13 (13%) |  < 5 (< 19%) | 10 (16%) | 28 (9%) |